Expands CNSide Clinical License in State of PennsylvaniaHOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the...
Cortigent is a leading developer of brain interface devices based on precision neurostimulation technology The company’s new Orion cortical stimulation...
Investigational ARC-BCI® Therapy is being developed to restore thought-driven movement in people living with spinal cord injuries and other movement...
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company...
BRAINTREE, Mass., Jan. 21, 2026 /PRNewswire/ -- MIB, the life insurance industry's trusted partner for data-driven insights and digital services,...
- Single Phase 2/3 Adaptive Study Design -- Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire...
ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company,...
Multi-year Sponsorship Expands Across Texas and California with Educational Resources, Community Leadership and Patient SupportBAKERSFIELD, Calif. and AUSTIN, Texas, Jan....
Dallas-based Restore Brain expands in Missouri, celebrating one year of advanced psychiatric care with innovative TMS and SPRAVATO® treatments Restore...
New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patientsBURLINGTON, Mass. and JERUSALEM,...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
CEO of family company Angelini Industries will also lead the pharmaceutical company from today, bringing strong leadership experience and strategic...
HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology Inc. (hereinafter referred to as "Hopstem"), a company dedicated to the...
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company...
Immersive AI Education & Experience for Home Care and Senior Living Leaders Not Yet Using SensiPALO ALTO, Calif., Jan. 20,...
Immersive AI Education & Experience for Home Care and Senior Living Leaders Not Yet Using SensiPALO ALTO, Calif., Jan. 20,...
Immersive AI Education & Experience for Home Care and Senior Living Leaders Not Yet Using SensiPALO ALTO, Calif., Jan. 20,...
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...